Peptide architecture
Sethera Weave
Interlaced polymacrocyclic peptides
Preclinical biotechnology
Radical peptide engineering
Advancing new medicines.
We are developing peptide therapeutics for cancer and immune-mediated disease, powered by proprietary enzymatic peptide engineering.
Peptide architecture
Sethera Tandem
Sequential polymacrocyclic peptides
Two architectures. A broader space for molecular design. Cross-links highlighted · Drag to explore
Our therapeutic focus
A clear purpose.
A focused path forward.
We scale peptide architecture and amino acid diversity to discover and advance new therapeutic possibilities.
Oncology
Restoring critical
tumor-suppressor function.
Developing peptide approaches aimed at restoring tumor-suppressor activity and addressing challenging cancer biology.
Our oncology approach
Our research brings peptide discovery and functional evaluation together to identify molecules with the potential to address disease-driving changes in tumor-suppressor biology.
Immunology
Precision in
inflammatory signaling.
Developing selective peptide approaches to modulate inflammatory pathways and pursue new options for immune-mediated disease.
Our immunology approach
Our goal is to connect precise molecular recognition with the functional activity needed to address inflammatory disease, supported by careful evaluation of receptor selectivity and developability.
The science behind our medicines
Diverse structures
create new possibilities.
Our approach uses enzymes to install cross-links that constrain peptide structure. Exploring sequence and architecture together gives us a distinctive foundation for discovering and optimizing molecules for challenging therapeutic targets.
Sethera’s enzymatic chemistry
INSIDE THE TRANSFORMATION
01 / 04SUBSTRATE POSITIONING
A peptide.
Positioned.
A peptide binds the enzyme, positioning a cysteine sulfur alongside an auxiliary iron–sulfur cluster.
THE CHEMICAL STEP SCHEMATIC
Enzyme–peptide modelPeptide · SAM · three iron–sulfur clusters
Molecular models illustrate peptide binding and thioether formation.
01 / Engineer
Explore molecular architecture.
We build and evaluate peptide structures with different cross-linking patterns and chemical features.
02 / Discover
Connect recognition to function.
Use screening and experimental evaluation to identify promising molecules and understand their activity.
03 / Advance
Build evidence for development.
Bring binding, function, selectivity, and developability into the decisions that guide program advancement.
Our design ambition
Inspired by nature.
Designed for delivery.
We look to nature’s molecular architectures to guide our peptide design. By combining enzymatic chemistry with amino acid diversity, we aim to bring stability, passive permeability, and oral bioavailability together in the same molecule.
Scientific foundation
Explore the research.
Our company
Scientific conviction.
Therapeutic ambition.
Sethera Therapeutics is a preclinical biotechnology company based in Salt Lake City. We bring together peptide chemistry, molecular biology, and translational development to pursue new medicines.
Karsten Eastman, PhD
Co-founder & Chief Executive Officer
Vahe Bandarian, PhD
Co-founder & Chief Scientific Officer
Scientific expertise
Supported by accomplished scientists and advisors across peptide engineering, protein science, and immunology.
Perspectives & progress
Ideas that move us forward.
Peptide innovator says the drug class is due for a rethink
Read moreDesigning Peptide Screens to Generate Knowledge, Not Just Hits
Read moreBase to Base biotech podcast 73: Polymacrocyclic peptides and AI in drug discovery and diagnosis
Read moreThe Potential of Peptide Drugs – Dr. Karsten Eastman, Co-Founder & CEO, Sethera Therapeutics
Read moreReceptor.AI and Sethera Plan to Create Closed-Loop Discovery and Optimization Workflow for Difficult Therapeutic Targets
Read moreHow enzyme chemistry is reshaping peptide drugs
Read morePartner with Sethera
Advance what comes next.
We welcome conversations around compelling therapeutic opportunities and focused collaborations.